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Study objective: The purpose of this study was to determine if an oxygen
prescription based on continuous oximetry monitoring, would result in an increased
percentage of time spent within an SpO2 level between 88% and 92%.
Methods: We conducted a prospective, cohort study in an outpatient, pulmonary
setting in a tertiary care referral center, on 17 patients with stable chronic
obstructive pulmonary disease (COPD) who had previously been prescribed long-term
oxygen therapy. The patients were monitored for 24 h with a portable oximeter
that recorded SpO2 and EKG readings. During the initial 24 h of monitoring, the
patients were on their previous oxygen prescription. Their oxygen prescription was
then altered based on a predetermined protocol described below. The patients were
then monitored for an additional 24 h.
Results: Sixteen patients completed the study. Based on the initial continuous
oximetry, the median oxygen prescription was reduced from 2.5 to 1.2 L/min
(Po0:001). The oxygen prescription during exercise, rest, and sleep decreased from
3.070.9 to 1.871.3 L/min (Po0:001), 2.270.4 to 0.870.7 L/min (Po0:001), and
2.270.4 to 0.970.8 L/min (Po0:001) respectively. After the oxygen prescription
was adjusted, the percentage of the time that the SpO2 was between 88 and 92%
increased from 24.8721.7% to 52.8725.0% (P ¼ 0:001), but the percentage of time
that the SpO2 was below 88% did not change significantly (2.876.1% to 4.378.1%).Elsevier Ltd. All rights reserved.
gas; COPD, chronic obstructive pulmonary disease; LTOT, long-term oxygen therapy; SaO2,
oglobin oxygen saturation as determined by pulse oximetry; PaO2, arterial oxygen pressure
C, Nashville, Tennessee and the Saint Thomas Foundation, Nashville, Tennessee.
of Pulmonary Medicine, Saint Thomas Hospital, 4220 Harding Road, Nashville 37205-2005,
+1 615 222 6564.
m (R.W. Light).
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Continuous oxygen monitoring—a better way to prescribe long-term oxygen therapy 1387Conclusions: This study demonstrates that an oxygen prescription based on
continuous oximetry monitoring results in (1) a significant increase in the percentage
of time that the SpO2 is between 88% and 92%, (2) a significant decrease in the
amount of oxygen prescribed, (3) a slight increase in the amount of time that the
SpO2 is below 88% that was not statistically significant.
& 2005 Elsevier Ltd. All rights reserved.Table 1 Inclusion criteria.Introduction
Chronic obstructive pulmonary disease (COPD)
causes more than 500,000 hospitalizations and
more than 100,000 deaths in the United States
each year.1,2 There is a general agreement that
patients with COPD who are developing chronic
respiratory failure benefit from long-term oxygen
therapy (LTOT). Two randomized trials have ad-
dressed the effect of domiciliary oxygen on the
mortality of patients with COPD.3,4 These trials
provided convincing evidence that LTOT can in-
crease the median survival of hypoxic patients with
COPD.
In the United States, more than 800,000 patients
receive LTOT with a cost of $1.8 billion annually.
LTOT accounts for approximately one-sixth of the
direct cost of COPD care.5–8 The current standards
for prescribing oxygen to patients with lung disease
recommend providing adequate flow of oxygen to
correct hypoxemia at rest and during usual ex-
ercise.3,4,9–11 Currently, clinical criteria for the
initiation of LTOT is based on a single measurement
of resting oxygen levels (either PaO2 o55mmHg or
a hemoglobin oxygen saturation SpO2o88%).12
Since the oxygenation status of patients fluctuates
throughout a 24 h period, a single measurement of
a resting oxygen level may not reflect the oxygen
needs of the patient.
We hypothesized that an oxygen prescription
based on continuous oximetry monitoring would
result in the SpO2 being within the targeted range a
higher percentage of the time. The purpose of this
study was to determine if an oxygen prescription,
based on the results of continuous oxygen monitor-
ing, would result in an increased percentage of
time spent with an SpO2 level between 88% and
92%.Inclusion criteria Patients with COPD who are
known to be compliant
based on a conversation
with the patient’s primary
pulmonologist.
Age 40–70
FEV1/FVC o60%
Currently receiving LTOT
Willing and able to receive
informed consentMaterials and methods
This prospective, cohort study was conducted in an
outpatient pulmonary setting at Saint Thomas
Hospital, Nashville, Tennessee, a tertiary care
referral center. The inclusion criteria of this study
are shown in Table 1. The diagnosis of COPD wasestablished based on commonly accepted criter-
ia.13,14 All patients were required to be receiving
continuous oxygen therapy for 24 h daily and to be
clinically stable. To be considered clinically stable,
a patient could not have had a COPD exacerbation
that required hospitalization, the administration of
antibiotics, or increased doses of steroids during
the preceding 2 months. Seventeen stable COPD
patients receiving LTOT enrolled into the protocol.
Each patient signed an informed consent. Spiro-
metric measurements were performed in all pa-
tients with ProfilerTM pulmonary function system
(MedGraphics Corp, Saint Paul, MN).
Continuous oxygen monitoring was performed on
two different days less than 7 days apart. During
the first day, all patients underwent continuous
oxygen monitoring for approximately 24 h with
their previous prescription of oxygen. Patients kept
a diary of their activities throughout the day. The
data from the first day of monitoring was reviewed
and adjustments were made in the oxygen pre-
scription based on their saturations during rest,
exercise and sleep. The mean SaO2 was estimated
by looking at the continuous printout and then
adjustments were made according to a pre-deter-
mined scheme (Table 2) in the oxygen prescription
during rest, exercise and sleep.
After the oxygen prescription was adjusted, the
patients underwent the second continuous oxime-
try monitoring for approximately 24 h. Of note,
patients were blinded to the Oximeter reading,
negating any bias secondary to the Hawthorne
effect.
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Table 2 Adjustments of the O2 prescription.
Mean SpO2(%) O2 prescription
495 Reduce by 2 L/min
92oSpO2p95 Reduce by 1 L/min
88pSpO2p92 No change
85pSpO2o88 Increase by 1 L/min
o85 Increase by 2 L/min
Z. Zhu et al.1388Continuous oximetry monitoring was performed
with the OxyHolter (OxyHolter LLC, Nashville, TN).
This device is a small, lightweight portable oxi-
meter that can continuously record SpO2 and pulse
rate for up to 24 h. Close attention was paid to
proper fixation of the oxygen-sensing device to the
finger of the patient to ensure stable recording.
Each parameter was recorded every 15 s. To assure
good-quality recording, the pulse oximeters were
powered by an alternating-current electricity
source. Recorded data were analyzed using com-
puter software (OxyHolter OxyTrend 4.0, Nashville,
TN). Artifacts such as an interruption of electricity
supply or displacement of the measuring cell were
recorded and influenced the quality index (Q). Q
was considered an expression of the ratio of
artifacts to the effective recording time. The mean
Q was 0.98.
The following measurements were obtained from
the pulse oximetry readings: the percentage of
total recording time spent with pulse oximeter
saturation of o88%, the percentage of total
recording time spent with an SpO2 level between
88% and 92%, and the percentage of total recording
time spent with pulse oximeter saturation of
492%. The study protocol was approved by the
Institutional Review Board of Vanderbilt University.
All patients gave written informed consent.Table 3 Lung function data in 17 COPD patientsa.
Variable Data
Age (yr) 64.078.0
FEV1 (L) 1.671.0
FVC (L) 2.671.0
FEV1/FVC (%) 47.378.2
aData are presented as mean+SD.Statistical analysis
Results of lung function tests and oximetry record-
ings are presented as the mean value7SD. Compar-
isons of the data obtained from oximetry recordings
regarding the percentage of the time spent with
various ranges of SpO2 and the amount of oxygen
that the patients received during the first and
second days of continuous oxygen monitoring were
made using the paired t-test or Wilcoxon signed
rank test depending on whether or not the data was
distributed normally (SigmaStat, version 2.0, Plo-
ver, WI).Results
Seventeen patients were initially enrolled in the
study. Details of patients’ characteristics are shown
in Table 3. The use of the portable oximeter was
well received by the patients. The majority of
patients found the portable unit easy to use and not
burdensome to wear. They reported minimal inter-
ference with the performance of their normal daily
activities in their patient logs. One patient was
found to have an SpO2 within the 88–92% range for
more than 75% of the initial 24-h period, and was
excluded from further study.
The remaining 16 patients were initially on a
median oxygen flow of 2.5 L/min overall, 3.0 L/min
on exercise, 2.2 L/min at rest, and 2.2 L/min while
sleeping (Table 4). It appeared that the patients
had been prescribed more oxygen than was
necessary. The SpO2 levels were above 92% during
72.5% of the total recording time and were below
88% during only 2.8% of the total recording time
(Table 4).
Based on the initial continuous oximetry, 81.3% of
patients (13/16) had their oxygen dose reduced.
The mean oxygen prescription was reduced sig-
nificantly from 2.570.5 to 1.270.9 L/min
(Po0:001). The mean oxygen prescriptions at rest,
during exercise, and during sleep were all reduced
significantly after the initial oximetry (Table 4).
Four patients receiving 2 L/min supplemental oxy-
gen had a mean SpO2 greater than 95% and
accordingly had their oxygen prescription reduced
to 0. With no oxygen, the percent of the time that
the SpO2 in these four patients remained below 88%
was 0, 1.5, 13, and 32. The two latter patients were
placed back on 1 L/min.
The adjustment of oxygen prescriptions, based
on the results of initial continuous oximetry
monitoring, resulted in an increase in the percen-
tage of time that the SpO2 level was between 88%
and 92%. After the oxygen prescription was
adjusted, the percentage of time that the SpO2
level was between 88% and 92% increased signifi-
cantly from 24.8721.7% to 52.8725.0%
(P ¼ 0:001). The reduction in the O2 prescription
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Table 4 Comparison of oxygen prescriptions on initial day and after adjustmenta.
Variables Initial Post-adjustment P-value
Mean O2 flow (L/min) 2.570.5 1.270.9 o0.001
O2 flow (exercise) (L/min) 3.070.9 1.871.3 o0.001
O2 flow (rest) (L/min) 2.270.4 0.870.7 o0.001
O2 flow (sleep) (L/min) 2.270.4 0.970.8 o0.001
aData are presented as mean+SD.
Table 5 Comparison of SpO2 on the monitoring days initially and after the oxygen prescription was changed.
Variables Initial day Post-adjustment day P-value
% time SpO2 o88% 2.876.1 4.378.1 0.326
88%p% time SpO2 p92% 24.8721.7 52.8725.0 0.001
% time SpO2 492% 72.5722.7 43.2728.2 0.002
*Data are presented as mean+SD. NS ¼ not significant.
Continuous oxygen monitoring—a better way to prescribe long-term oxygen therapy 1389did not lead to a significant increase in the
percentage of time that the SaO2 was below 88%.
The percentage of time spent within an SpO2 level
below 88% did not significantly change (from
2.876.1% to 4.378.1%, P ¼ 0:33)(Table 5). How-
ever, the power of the test to detect a significant
difference given the observed numbers was only
0.15. However, the percentage of the time that the
SpO2 was above 92% was reduced from 72.5722.7%
to 43.2728.2% (P ¼ 0:002).Discussion
The goal of our study was to evaluate whether an
oxygen prescription based on continuous oximetry
monitoring would result in an increase in the
percentage of time that the SpO2 was in a targeted
range. The present study demonstrates that oxygen
prescription based on continuous oximetry mon-
itoring results in a significant increase in the
percentage of time the SpO2 is between 88% and
92%. We also found the adjustment of the oxygen
prescription, based on the continuous oximetry
monitoring, resulted in approximately a 50% de-
crease in the amount of oxygen consumed without
a significant change in the amount of time the SpO2
was below 88%.
LTOT is the only treatment that has been shown
to improve survival in COPD patients with severe
hypoxemia. In general, the more hours per dayoxygen is used, the greater the reduction in
mortality.3,4 In addition to a reduction in mortality,
LTOT may also have the following benefits: a
reduction in hypoxemia-induced elevations in he-
moglobin,3,15 decreased pulmonary artery pressure
and vascular resistance, increased stroke volume
index,3,15–18 improved exercise tolerance,4,19,20
increased functional status, and subjective im-
provement in quality of life.21,22
The current approach to prescribing LTOT, using a
static assessment of SpO2 at one point in time, is
derived from two multicentered, prospective trials
that investigated the effect of oxygen supplemen-
tation on survival in COPD patients.3,4 In these
studies, oxygenation was monitored by measuring
the PaO2 in ABG samples obtained intermittently in
the hospital or clinic setting, and an attempt was
made to maintain a PaO2 between 60 and 80mmHg.
Since the oxygenation status of patients fluctuates
throughout a 24 h period, a single measurement of
a resting oxygen level may not reflect the actual
oxygen needs of the patient.
More than 15 years ago, Decker et al. performed
preliminary studies of continuous oximetry mon-
itoring, and found the procedure potentially fea-
sible.23–25 In the past decade, there have been
significant technical improvements in the equip-
ment used for continuous oximetry monitoring. The
latest generations of oximeters are capable of
recording, storing, and then downloading data to a
computer for further analysis. Recently, several
studies reported the advantages of continuous
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Z. Zhu et al.1390oximeter monitoring in patients with COPD.26–28
Similar to these studies, we found continuous
oximeter monitoring feasible with a high degree
of patient acceptance, and the capability of
producing acceptable data 492% of the total
recording time. These results show an improvement
over earlier attempts to implement this technique
in human subjects.23–26
While previous studies focused on detecting
desaturation during sleep or exercise,26–28 our
study focused on providing the appropriate amount
of supplemental oxygen to the COPD patient to
maintain a SaO2 between 88% and 92%. We readily
acknowledge that the SaO2 target value, which is
associated with the maximal clinical benefit, is not
definitely known.
In the Nocturnal Oxygen Therapy Trial, monthly
arterial blood gas measurements were used to
adjust the oxygen dose
’ ’
to maintain a PaO2 of 60 to
80mmHg’’ with an
’ ’
automatic increase of 1 L/min
during exercise and sleep’’.4 In the British Medical
Research Council study, oxygen prescriptions were
reassessed bimonthly using arterial samples, with a
target resting value of PaO2460mmHg.
3 Neither
study determined SpO2 while patients were en-
gaged in normal activities of daily living. The
optimal daily duration of oxygen supplementation
and the optimal SpO2 target value for maximal
clinical benefit are still not precisely known.29–33
These studies concluded that patients with hypox-
emia (resting PaO2o55mmHg or SpO2o88%) should
receive oxygen supplementation
’ ’
continuously,’’
because the benefits were proportional to the
duration of treatment. According to the last
guideline on management of COPD, LTOT is in-
dicated for COPD patients with a PaO2 less than
55mm Hg. Oxygen therapy should not be given to
stable patients with oxygen saturations 492%
breathing room air.12 In our study, we set up an
SpO2 target of 88–92%, and adjusted the oxygen
prescription based on this target.
We found that the adjustment of the oxygen
prescription based on the results of continuous
oximeter monitoring resulted in a significant
increase in the percentage of time spent with an
SpO2 level between 88% and 92%. Although the
mean oxygen dose was decreased by approximately
50% after the adjustment of the oxygen prescrip-
tion, there was not a significant increase in the
percentage of time that the SpO2 was below 88%.
Although LTOT is a well-established treatment
that improves survival and quality of life in
chronically hypoxemic patients with COPD, LTOT
imposes a substantial economic burden to the
health care system. Nearly 800,000 patients in
the United States receive LTOTannually, at a yearlycost of $1.8 billion. Oxygen accounts for approxi-
mately one-sixth of the direct cost of COPD care.5–8
However, are most oxygen prescriptions for COPD
patients at the appropriate level? Yuji Oba et al.
performed a cross-sectional retrospective study to
examine how often orders for LTOT were reeval-
uated and to assess the impact that reevaluation
would have on the cost of LTOT. They found that up
to 60% of patients could potentially be discontinued
from LTOT if they were reevaluated by pulse
oximetry or ABG measurement within 1–3 months
after initiation of oxygen therapy.34 Taking these
numbers into consideration, it is possible that more
than 30,000 COPD patients remain on unnecessary
LTOT in the United States, and discontinuing
unnecessary oxygen concentrators could possibly
save $106–153 million per year . In the present
study, we found that the adjustment of the oxygen
prescription based on the results of continuous
oxygen monitoring resulted in approximately a 50%
decrease in the amount of oxygen prescribed
without a significant increase in the time of
desaturation.
Several possible limitations of our study deserve
comment. First, our observations were based on a
small number of patients from a single hospital,
and it is unclear whether our results can be
extrapolated to the entire population of COPD
patients. Second, we did not obtain arterial blood
for ABG analysis. Therefore, we did not validate the
readings by our oximeter as has been done in a
previous study.35 However, the validity of the
Oxyholter has been verified by the FDA. Moreover,
in our experience, the majority of clinicians do not
measure PaO2 values when adjusting LTOT, because
it is invasive and time-consuming. Third, we did not
directly monitor compliance with the oxygen
prescription in each patient, as was done in the
classic LTOT trials.3,4 Instead, we based our
estimate of compliance on subjective patient
response by requesting that patients note any
deviations from their prescriptions in their log.
Therefore, we may have overestimated patient
compliance with their oxygen prescriptions. Never-
theless, we believe that the compliance was
excellent because changes in the SpO2 were
parallel to the changes in the oxygen prescription,
as expected.
In conclusion, continuous oximetry monitoring is
a feasible method for monitoring SpO2 in the
outpatient setting, and should be evaluated further
as a tool for optimizing LTOT. The prescription of
oxygen based on the use of the continuous oxygen
monitoring with a targeted SpO2 of 88–92% resulted
in (1) a significant increase from 22% to 48% in the
percentage of time that the SpO2 was between 88%
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amount of oxygen prescribed; and (3) only a slight
increase in the amount of time that the SpO2 is
below 88% that was not statistically significant. The
optimal SpO2 for patients with COPD remains to be
determined. Long-term studies assessing various
targeted SpO2’s are needed to define this optimal
SpO2. The present study demonstrates that con-
tinuous oxygen monitoring is a feasible method by
which the targeted SpO2 can be achieved.Acknowledgments
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